GlaxoSmithKline taps Unilever as lead bidder in Indian Horlicks buyout: report

GlaxoSmithKline GSK House in Brentford, UK
GlaxoSmithKline has been working to sell its Indian Horlicks business after kicking off a review in March. (GSK)

GlaxoSmithKline has been working to unload its Indian consumer products business, including the nutritional beverage Horlicks, and now the company may be almost there.

Following a monthslong bidding process that in October reportedly centered on potential buyers Nestlé, Coca-Cola and Unilever, Unilever is now the leading bidder, Reuters reports.

While the Financial Times reported on Tuesday that the talks were exclusive, one source told Reuters that GSK could reopen talks with Nestlé if the drugmaker is unable to strike a deal with Unilever.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Back in March, Glaxo said it’d be reviewing options for Horlicks and other nutrition products that generated £550 million last year, with India contributing most of that haul. GSK is weighing a 72.5% holding in the company, called GlaxoSmithKline Consumer Healthcare Ltd.

Along the way, reports surfaced that food company Danone, private equity firm KKR, PepsiCo and others were interested in a buyout. But in October, The Economic Times' sources told the Indian newspaper the deal talks came to a final bidding round between Coca-Cola, Nestlé and Unilever.  

RELATED: Nestlé, Coca-Cola and Unilever in final bidding war for GSK's Horlicks: report 

The sale could reportedly generate up to $4 billion, much-needed cash for GlaxoSmithKline after the drugmaker agreed in March to purchase Novartis’ share in their consumer joint venture for $13 billion. 

Despite its ongoing consumer sale process in India, GSK has stressed that it's not backing away from the Indian market altogether. The drugmaker plans to back OTC and oral health brands in the country as well as invest in prescription drugs and vaccines, executives have said. 

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.